NRx Advances NRX-100 Toward Full FDA Approval Path

NRX Pharmaceuticals ( (NRXP) ) has provided an announcement.

On February 17, 2026, NRx Pharmaceuticals announced it had completed an in-person Type C meeting with senior U.S. FDA officials, together with partner Osmind, that clarified a regulatory path for NRX-100, its preservative-free intravenous ketamine. Based on oral guidance, the company believes existing controlled trial data, supplemented by real-world evidence from more than 65,000 patients in Osmind’s database, may support a full New Drug Application rather than the previously anticipated accelerated approval route.

NRx plans to seek an indication for treatment-resistant depression in the context of suicidality, a broader target than its earlier focus on suicidal ideation alone, and anticipates submitting the NDA in the second quarter of 2026 with a potential PDUFA decision later that year. The FDA indicated that the proposed clinical endpoints may be acceptable for full approval, that no additional nonclinical or bridging studies are required for the preservative-free formulation, and agreed to collaborate on the statistical plan for the real-world dataset, while a separate abbreviated application for preservative-free ketamine in anesthesia and pain remains under review with an expected decision in summer 2026.

The most recent analyst rating on (NRXP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.

Spark’s Take on NRXP Stock

According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.

The score is held down primarily by weak financial performance (large losses, ongoing cash burn, and negative equity) and bearish technicals (price below key moving averages with negative MACD). This is partially offset by a more positive earnings-call outlook tied to initial revenue generation, clinic expansion plans, and drug-approval progress, while valuation is difficult to assess due to negative earnings and no provided dividend yield.

To see Spark’s full report on NRXP stock, click here.

More about NRX Pharmaceuticals

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system disorders, including suicidal depression, chronic pain and PTSD. Its pipeline centers on its NMDA platform, notably NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone combination, both targeting severe mood and depressive conditions in high-risk patient populations.

NRX-100 has received Fast Track designation for suicidal ideation in depression, including bipolar depression, while NRX-101 holds Breakthrough Therapy designation for suicidal bipolar depression. The company is pursuing both an Abbreviated New Drug Application for a generic preservative-free ketamine formulation in anesthesia and pain, and a New Drug Application for NRX-100 in psychiatric indications, positioning NRx within a competitive, fast-evolving neuropsychiatry market.

Average Trading Volume: 924,385

Technical Sentiment Signal: Sell

Current Market Cap: $53.29M

Learn more about NRXP stock on TipRanks’ Stock Analysis page.